Teva pays $6.8B to buy Cephalon, including Minnesota's CIMA Labs

Drug delivery company CIMA Labs in Brooklyn Park, Minnesota, will come under Israeli firm Teva Pharmaceutical (Nasdaq: TEVA  ) as part of Teva's acquisition of CIMA parent company Cephalon (Nasdaq: CEPH  ) , a pharmaceutical company which is based in Frazer, Pennsylvania.

Teva and Cephalon announced today that Teva will pay $81.50 per share of each outstanding Cephalon share, making the deal worth about $6.8 billion. The deal is expected to close in the third quarter and will require no financing. Teva is paying a 39 percent premium to buy Cephalon based on the company's closing stock price on March 29, the last closing price before the unsolicited proposal was announced.

The companies announced that the acquisition would provide cost synergies of $500 million and broaden Teva's reach into therapeutic areas including CNS, oncology, respiratory,Teva di and pain management. The combined company's sales are about $7 billion based on branded portfolio drugs already available and more than 30 late-stage compounds being developed.

"This is transforming for Teva's branded business, as it will help us to deliver on our strategic goal of creating a diversified, multi-faceted company," said Shlomo Yanai, president and CEO of Teva, in a statement."We have been following Cephalon for a long time and are very happy with the opportunity to join forces."

"Cephalon's merger with Teva is the result of a rigorous process that included a review of a wide range of strategic options undertaken by Cephalon's Board of Directors and management team to maximize value and deliver significant returns to shareholders," said Kevin Buchi, Cephalon's CEO, in a statement.

Cephalon acquired CIMA Labs, the Minnesota entity, in 2004. CIMA Labs also has manufacturing facilities in Eden Prairie, Minnesota, and Salt Lake City, Utah. In Europe, its R&D operations and manufacturing facility are in France.

Teva Pharmaceutical Industries is a Motley Fool Global Gains pick. The Fool owns shares of Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1486263, ~/Articles/ArticleHandler.aspx, 10/26/2014 2:01:29 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement